

Human IL-1 β Monoclonal Antibody

Catalog No.: YR0006

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/ μ g) Determined by LAL gel clotting assay

Sterility

0.2 μ m filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Canakinumab is a recombinant human monoclonal antibody which binds to IL-1 β (interleukin-1 beta). It's mode of action is based on the neutralization of IL-1 β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it's use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Canakinumab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Recommended Isotype Control(s)

Recommended Dilution Buffer

1xPBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)